Skip to main content
SpringerLink
Log in

Posttransplant Lymphoproliferative Disorder

  • Chapter
Infectious Causes of Cancer

Part of the book series: Infectious Disease ((ID))

  • 229 Accesses

Abstract

Recognized since the early days of organ transplantation, Epstein-Barr virus (EBV)-associated B-lymphoproliferative disorders remain a major complication of immunosuppression. Similar if not identical EBV-associated B-cell proliferations have since been described in congenital and in other acquired immunodeficiency states. Although the initial events in the course of viral lymphomagenesis appear to be unique to the setting of immunodeficiency, the subsequent evolution of lesions more closely resembles lymphomas seen in the general population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Penn I. Cancer in the immunosuppressed organ recipient. Transplant Proc 1991; 23: 1771–1772.

    PubMed  CAS  Google Scholar 

  2. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877–86.

    PubMed  CAS  Google Scholar 

  3. Opelz G, Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 1993; 342: 1514–1516.

    Article  PubMed  CAS  Google Scholar 

  4. Opelz G. Are post-transplant lymphomas inevitable? [editorial]. Nephrol Dialys Transplant 1996; 11: 1952–1955.

    Article  CAS  Google Scholar 

  5. Ho M, Jaffe R, Miller G, et al. The frequency of Epstein—Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation 1988; 45: 719–727.

    Article  PubMed  CAS  Google Scholar 

  6. Cacciarelli TV, Esquivel CO, Moore DH, et al. Factors affecting survival after orthotopic liver transplantation in infants. Transplantation 1997; 64: 242–248.

    Article  PubMed  CAS  Google Scholar 

  7. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723–1728.

    Article  PubMed  CAS  Google Scholar 

  8. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995; 14: 214–221.

    PubMed  CAS  Google Scholar 

  9. Nalesnik MA, Rao AS, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997; 63: 1200–1205.

    Article  PubMed  CAS  Google Scholar 

  10. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.

    Article  PubMed  CAS  Google Scholar 

  11. Beveridge T, Krupp P, McKibbin C. Lymphomas and lymphoproliferative lesions developing under cyclosporin therapy [letter]. Lancet 1984; 1: 788.

    Article  PubMed  CAS  Google Scholar 

  12. Armitage JM, Fricker FJ, del Nido P, Starzl TE, Hardesty RL, Griffith BP. A decade (1982 to 1992) of pediatric cardiac transplantation and the impact of FK 506 immunosuppression. J Thorac Cardiovasc Surg 1993; 105: 464–472.

    PubMed  CAS  Google Scholar 

  13. Deschler DG, Osorio R, Ascher NL, Lee KC. Posttransplantation lymphoproliferative disorder in patients under primary tacrolimus (FK 506) immunosuppression. Arch Otolaryngol Head Neck Surg 1995; 121: 1037–1041.

    Article  PubMed  CAS  Google Scholar 

  14. Cacciarelli TV, Esquivel CO, Cox KL, et al. Oral tacrolimus (FK506) induction therapy in pediatric orthotopic liver transplantation. Transplantation 1996; 61: 1188–1192.

    Article  PubMed  CAS  Google Scholar 

  15. Bach JF, Chatenoud L. Immunologic monitoring of Orthoclone OKT3-treated patients: the problem of antimonoclonal immune response. Transplant Proc 1987; 19: 17–20.

    PubMed  CAS  Google Scholar 

  16. Walker RC, Marshall WF, Strickler JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995; 20: 1346–1353.

    Article  PubMed  CAS  Google Scholar 

  17. Penn I. The changing pattern of posttransplant malignancies. Transplant Proc 1991; 23: 1101–1103.

    PubMed  CAS  Google Scholar 

  18. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.

    PubMed  CAS  Google Scholar 

  19. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia [see comments]. N Engl J Med 1989; 321: 784–789.

    Article  PubMed  CAS  Google Scholar 

  20. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–1243.

    PubMed  CAS  Google Scholar 

  21. Purtilo DT. Epstein-Barr-virus-induced oncogenesis in immune-deficient individuals. Lancet 1980; 1: 300–303.

    Article  PubMed  CAS  Google Scholar 

  22. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981; 41: 4253–4261.

    PubMed  CAS  Google Scholar 

  23. Young L, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080–1085.

    Article  PubMed  CAS  Google Scholar 

  24. Randhawa PS, Jaffe R, Demetris AJ, et al. Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med 1992; 327: 1710–1714.

    Article  PubMed  CAS  Google Scholar 

  25. Klein G. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution. Proc Natl Acad Sci USA 1979; 76: 2442–2446.

    Article  PubMed  CAS  Google Scholar 

  26. Cleary ML, Nalesnik MA, Shearer WT, Sklar J. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood 1988; 72: 349–352.

    PubMed  CAS  Google Scholar 

  27. Kaplan MA, Ferry JA, Harris NL, Jacobson JO. Clonal analysis of posttransplant lymphoproliferative disorders, using both episomal Epstein-Barr virus and immunoglobulin genes as markers. Am J Clin Pathol 1994; 101: 590–596.

    PubMed  CAS  Google Scholar 

  28. Riddler SA, Breinig MC, McKnight JL. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients. Blood 1994; 84: 972–984.

    PubMed  CAS  Google Scholar 

  29. Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103.

    PubMed  CAS  Google Scholar 

  30. Hopwood P, Brooks LA, MacCormac L, et al. Changes in Epstein-Barr virus load in the peripheral blood following cardiothoracic transplantation (abstr.). Eighth International Symposium on Tumor-Associated Herpesviruses, 1998, p. 5.

    Google Scholar 

  31. George D, Barnett L, Boulad F, et al. Semi-quantitative PCR analysis of genomic EBV DNA post BMT allows close surveillance of patients at risk for development of EBV-lymphoproliferative disorders (EBV-LPD) allowing prompt intervention (abstr.). Blood 1998; 92 (Suppl 1): 437a.

    Google Scholar 

  32. Swinnen LJ, Gulley ML, Hamilton E, Schichman SA. EBV DNA quantitation in serum is highly correlated with the development and regression of post-transplant lymphoproliferative disorder (PTLD) in solid organ transplant recipients (abstr.). Blood 1998; 92 (Suppl. 1): 314–315.

    Google Scholar 

  33. Cen H, Williams PA, McWilliams HP, Breinig MC, Ho M, McKnight JLC. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with post-transplant lymphoproliferative disorders. Blood 1993; 81: 1393–1403.

    PubMed  CAS  Google Scholar 

  34. Delecluse HJ, Kremmer E, Rouault JP, Cour C, Bornkamm G, Berger F. The expression of Epstein-Barr virus latent proteins is related to the pathological features of post-transplant lymphoproliferative disorders. Am J Pathol 1995; 146: 1113–1120.

    PubMed  CAS  Google Scholar 

  35. Rea D, Fourcade C, Leblond V, et al. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation. Transplantation 1994; 58: 317–324.

    PubMed  CAS  Google Scholar 

  36. Murray PG, Swinnen LJ, Constandinou CM, et al. BCL-2 but not its Epstein-Barr virus-encoded homologue, BHRF1, is commonly expressed in posttransplantation lymphoproliferative disorders [see comments]. Blood 1996; 87: 706–711.

    PubMed  CAS  Google Scholar 

  37. Izumi KM, Kieff ED. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc Natl Acad Sci USA 1997; 94: 12592–12597.

    Article  PubMed  CAS  Google Scholar 

  38. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J 1997; 16: 6478–6485.

    Article  PubMed  CAS  Google Scholar 

  39. Devergne O, Hatzivassiliou E, Izumi KM, et al. Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol Cell Biol 1996; 16: 7098–7108.

    PubMed  CAS  Google Scholar 

  40. Liebowitz D. Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998; 338: 1413–1421.

    Article  PubMed  CAS  Google Scholar 

  41. Rickinson AB. Epstein-Barr virus in action in vivo. N Engl J Med 1998; 338: 1461–1463.

    Article  PubMed  CAS  Google Scholar 

  42. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530–534.

    Article  PubMed  CAS  Google Scholar 

  43. Chadburn A, Suciu-Foca N, Cesarman E, Reed E, Michler RE, Knowles DM. Post-transplantation lymphoproliferative disorders arising in solid organ transplant recipients are usually of recipient origin. Am J Pathol 1995; 147: 1862–1870.

    PubMed  CAS  Google Scholar 

  44. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748–755.

    PubMed  CAS  Google Scholar 

  45. Gulley ML, Schneider BG, Swinnen U. Origin of post-transplant lymphoproliferative disorder ( PTLD) arising in solid organ recipients (abstr. ). Eighth International Symposium on Tumor-Associated Herpesviruses 1998, p. 85.

    Google Scholar 

  46. Frizzera G, Hanto DW, Gajl-Peczalska KJ, et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262–4279.

    PubMed  CAS  Google Scholar 

  47. Nalesnik MA, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173–192.

    PubMed  CAS  Google Scholar 

  48. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552–565.

    PubMed  CAS  Google Scholar 

  49. Cleary ML, Warnke R, Sklar J. Monoclonality of lymphoproliferative lesions in cardiac-transplant recipients. Clonal analysis based on immunoglobulin-gene rearrangements. N Engl J Med 1984; 310: 477–482.

    Article  PubMed  CAS  Google Scholar 

  50. Hanto DW, Birkenbach M, Frizzera G, Gajl-Peczalska KJ, Simmons RL, Schubach WH. Confirmation of the heterogeneity of posttransplant Epstein-Barr virus-associated B cell proliferations by immunoglobulin gene rearrangement analyses. Transplantation 1989; 47: 458–464.

    Article  PubMed  CAS  Google Scholar 

  51. Chadburn A, Cesarman E, Liu YF, et al. Molecular genetic analysis demonstrates that multiple posttransplantation lymphoproliferative disorders occurring in one anatomic site in a single patient represent distinct primary lymphoid neoplasms. Cancer 1995; 75: 2747–2756.

    Article  PubMed  CAS  Google Scholar 

  52. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989; 135: 977–987.

    PubMed  CAS  Google Scholar 

  53. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 8–14.

    PubMed  CAS  Google Scholar 

  54. Nelson BP, Nalesnik MA, Locker JD. EBV negative post-transplant lymphoproliferative disorders: a distinct entity? (abstr.). Lab Invest 1996; 74: 118A.

    Google Scholar 

  55. Van Gorp J, Doornewaard H, Verdonck LF, Klopping C, Vos PF, van den Tweel JG. Posttrans-plant T-cell lymphoma. Report of three cases and a review of the literature. Cancer 1994; 73: 3064–3072.

    Article  PubMed  Google Scholar 

  56. Hanto DW, Gajl-Peczalska KJ, Frizzera G, et al. Epstein-Barr virus (EBV) induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation. Clinical, pathologic, and virologic findings and implications for therapy. Ann Surg 1983; 198: 356–369.

    Article  PubMed  CAS  Google Scholar 

  57. Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Prob Surg 1988; 25: 367–472.

    Article  CAS  Google Scholar 

  58. Swinnen LJ, Mullen GM, Can TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 3333–3340.

    PubMed  CAS  Google Scholar 

  59. Morrison VA, Dunn DL, Manivel JC, Gajlpeczalska KJ, Peterson BA. Clinical characteristics of post-transplant lymphoproliferative disorders. Am J Med 1994; 97: 14–24.

    Article  PubMed  CAS  Google Scholar 

  60. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995; 13: 961–968.

    PubMed  CAS  Google Scholar 

  61. Cesarman E, Chadburn A, Liu YF, Migliazza A, Dalla-Favera R, knowles DM. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood 1998; 92: 2294–2302.

    PubMed  CAS  Google Scholar 

  62. Hanto DW, Frizzera G, Gajl-Peczalska KJ, et al. Epstein-Barr virus-induced B-cell lymphoma after renal transplantation: acyclovir therapy and transition from polyclonal to monoclonal B-cell proliferation. N Engl J Med 1982; 306: 913–918.

    Article  PubMed  CAS  Google Scholar 

  63. Filipovich AH, Mathur A, Kamat D, Kersey JH, Shapiro RS. Lymphoproliferative disorders and other tumors complicating immunodeficiencies. [Review]. Immunodeficiency 1994; 5: 91–112.

    PubMed  CAS  Google Scholar 

  64. McDiarmid SV, Jordan S, Lee GS, et al. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients. Transplantation 1998; 66: 1604–1611.

    Article  PubMed  CAS  Google Scholar 

  65. Shapiro RS, Chauvenet A, McGuire W, et al. Treatment of B-cell lymphoproliferative disorders with interferon alfa and intravenous gamma globulin [letter]. N Engl J Med 1988; 318: 1334.

    Article  PubMed  CAS  Google Scholar 

  66. Liebowitz D, Anastasi J, Hagos F, LeBeau MM, Olopade OI. Post-transplant lymphoproliferative disorders (PTLD): clinicopathologic characterization and response to immunomodulatory therapy with interferon-alpha (abstr.). Ann Oncol 1996; 7: 28.

    Google Scholar 

  67. Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324: 1451–1456.

    Article  PubMed  CAS  Google Scholar 

  68. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-Lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137–3147.

    PubMed  CAS  Google Scholar 

  69. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein—Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330: 1185–1191.

    Article  PubMed  CAS  Google Scholar 

  70. Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein—Barr-virus-related lymphoproliferation. Lancet 1995; 345: 9–13.

    Article  PubMed  CAS  Google Scholar 

  71. O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L. Biology and adoptive cell therapy of Epstein—Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997; 157: 195–216.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Lode J. Swinnen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Viral Epidemiology Branch, National Cancer Institute, 6120 Executive Blvd., Room 8012, MSC 7248, 20852, Rockville, MD, USA

    James J. Goedert MD (Chief) (Chief)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Swinnen, L.J. (2000). Posttransplant Lymphoproliferative Disorder. In: Goedert, J.J. (eds) Infectious Causes of Cancer. Infectious Disease. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-024-7_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-024-7_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9621-5

  • Online ISBN: 978-1-59259-024-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation